Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Health and Healing Research Education and Service, Boston, MA, USA.
Integr Cancer Ther. 2024 Jan-Dec;23:15347354241293197. doi: 10.1177/15347354241293197.
The Radical Remission Multimodal Intervention (RRMI) was developed by Kelly A. Turner, PhD, after analyzing more than 1500 cases of cancer survivors experiencing radical remission (a.k.a. spontaneous regression) across all cancer types and extracting key lifestyle factors shared by these cancer survivors. The RRMI workshops provide instruction on these lifestyle factors to participants with cancer and give them tools to help navigate their cancer recovery journey. This pilot study aimed to evaluate the effect of the RRMI on the quality of life (QOL) of people with cancer. This was a pre-post outcome study. Data were collected, between January 2019 and January 2022, from 200 eligible adults of all cancer types, who attended the RRMI workshops (online and in-person). Participants were asked to complete questionnaires online, at baseline (i.e., before the intervention) and at month 1 and month 6 post-intervention. The RRMI workshops were led by certified Radical Remission health coaches. Participants completed the RRMI with personalized action plans for them to implement. The primary outcome QOL measure was the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale (FACIT-Sp). Mixed-effects regression models were used to examine differences in FACIT-Sp score between month 1 and baseline, as well as month 6 and baseline. Models controlled for baseline score, covariates (including age, ethnic group, and body mass index), timepoints (month 1 or 6), training type (online or in-person), adherence score, and interaction between timepoints and adherence score. 92% of participants were women, 77% were Non-Hispanic White, 88% were living in the US, and 66.5% were not living alone. One-quarter had breast cancer. Mean age ± SD was 55.3 ± 11.5 years. Final mixed-effects model analyses showed a significant increase in FACIT-Sp score of 9.5 (95% confidence interval [CI]: 6.2-12.8) points at month 1 ( < .0001) and 9.7 (95% CI: 6.4-13.0) points at month 6 ( < .0001) compared with baseline, a 7.7% and 10.8% improvement, respectively. The RRMI was found to significantly improve the overall QOL of participants at month 1. This improvement was maintained at month 6 post-intervention. Our findings suggest that people with cancer can benefit from the RRMI.
激进缓解多模式干预 (RRMI) 是由 Kelly A. Turner, PhD 博士开发的，他在分析了超过 1500 例经历激进缓解（又称自发回归）的癌症幸存者的案例后，从所有癌症类型中提取了这些癌症幸存者共有的关键生活方式因素。RRMI 研讨会为癌症患者提供了有关这些生活方式因素的指导，并为他们提供了帮助他们度过癌症康复之旅的工具。这项初步研究旨在评估 RRMI 对癌症患者生活质量 (QOL) 的影响。这是一项前后测研究。2019 年 1 月至 2022 年 1 月期间，从参加 RRMI 研讨会（线上和线下）的所有癌症类型的 200 名合格成年人中收集了数据。参与者被要求在干预前（即干预前）和干预后 1 个月和 6 个月在线完成问卷。RRMI 研讨会由经过认证的激进缓解健康教练主持。参与者完成了 RRMI，并为他们制定了个性化的行动计划。主要的 QOL 测量指标是慢性疾病治疗的功能评估-精神幸福感量表 (FACIT-Sp)。混合效应回归模型用于检查干预后 1 个月和基线、6 个月和基线之间 FACIT-Sp 评分的差异。模型控制了基线评分、协变量（包括年龄、族裔和体重指数）、时间点（1 个月或 6 个月）、培训类型（线上或线下）、依从性评分以及时间点和依从性评分之间的交互作用。92%的参与者为女性，77%为非西班牙裔白人，88%居住在美国，66.5%不独居。四分之一的参与者患有乳腺癌。平均年龄为 55.3 ± 11.5 岁。最终的混合效应模型分析显示，与基线相比，FACIT-Sp 评分在第 1 个月时显著增加了 9.5（95%置信区间 [CI]：6.2-12.8）点（ < .0001），在第 6 个月时增加了 9.7（95% CI：6.4-13.0）点（ < .0001），分别提高了 7.7%和 10.8%。RRMI 被发现显著改善了参与者在第 1 个月的整体 QOL。这种改善在干预后 6 个月时仍然存在。我们的研究结果表明，癌症患者可以从 RRMI 中受益。
Cochrane Database Syst Rev. 2022-2-1
Palliat Support Care. 2017-8
Psychooncology. 2008-9
J Integr Med. 2024-5
Mayo Clin Proc Innov Qual Outcomes. 2024-3-4
J Clin Transl Res. 2023-3-28
Int J Environ Res Public Health. 2023-1-13
Int J Environ Res Public Health. 2022-5-3
Cancer Treat Res. 2021
Zotero 插件
